|
|
Taiwan Academic Institutional Repository >
Browse by Author
|
"ryu mh"
Showing items 1-14 of 14 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 國家衛生研究院 |
2024-08-20 |
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 tri
|
Boku, N;Omori, T;Shitara, K;Sakuramoto, S;Yamaguchi, K;Kato, K;Kadowaki, S;Tsuji, K;Ryu, MH;Oh, DY;Oh, SC;Rha, SY;Lee, KW;Chung, IJ;Sym, SJ;Chen, LT;Chen, JS;Bai, LY;Nakada, T;Hagihara, S;Makino, R;Nishiyama, E;Kang, YK |
| 國家衛生研究院 |
2022-02 |
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): A randomised, multicentre, double-blind, placebo-contr
|
Kang, YK;Chen, LT;Ryu, MH;Oh, DY;Oh, SC;Chung, HC;Lee, KW;Omori, T;Shitara, K;Sakuramoto, S;Chung, IJ;Yamaguchi, K;Kato, K;Sym, SJ;Kadowaki, S;Tsuji, K;Chen, JS;Bai, LY;Oh, SY;Choda, Y;Yasui, H;Takeuchi, K;Hirashima, Y;Hagihara, S;Boku, N |
| 國家衛生研究院 |
2021-09-04 |
Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: Post hoc subanalysis from the ATTRACTION-2 study
|
Kang, YK;Morita, S;Satoh, T;Ryu, MH;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yeh, KH;Yoshikawa, T;Oh, SC;Bai, LY;Tamura, T;Lee, KW;Hamamoto, Y;Kim, JG;Chin, K;Oh, DY;Minashi, K;Cho, JY;Tsuda, M;Sameshima, H;Chen, LT;Boku, N |
| 國家衛生研究院 |
2021-03-20 |
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
|
Boku, N;Satoh, T;Ryu, MH;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yeh, KH;Yoshikawa, T;Oh, SC;Bai, LY;Tamura, T;Lee, KW;Hamamoto, Y;Kim, JG;Chin, K;Oh, DY;Minashi, K;Cho, JY;Tsuda, M;Nishiyama, T;Chen, LT;Kang, YK |
| 國家衛生研究院 |
2020-09 |
Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study
|
Boku, N;Ryu, MH;Oh, DY;Oh, SC;Chung, HC;Lee, KW;Omori, T;Shitara, K;Sakuramoto, S;Chung, IJ;Yamaguchi, K;Kato, K;Sym, SJ;Kadowaki, S;Tsuji, K;Chen, JS;Bai, LY;Chen, LT;Kang, YK |
| 國家衛生研究院 |
2019-12-20 |
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
|
Chen, LT;Satoh, T;Ryu, MH;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yeh, KH;Yoshikawa, T;Oh, SC;Bai, LY;Tamura, T;Lee, KW;Hamamoto, Y;Kim, JG;Chin, K;Oh, DY;Minashi, K;Cho, JY;Tsuda, M;Sameshima, H;Kang, YK;Boku, N |
| 國家衛生研究院 |
2019-05-13 |
Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: A randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer
|
Satoh, T;Kang, YK;Chao, Y;Ryu, MH;Kato, K;Cheol Chung, H;Chen, JS;Muro, K;Ki Kang, W;Yeh, KH;Yoshikawa, T;Oh, SC;Bai, LY;Tamura, T;Lee, KW;Hamamoto, Y;Kim, JG;Chin, K;Oh, DY;Minashi, K;Cho, JY;Tsuda, M;Tanimoto, M;Chen, LT;Boku, N |
| 國家衛生研究院 |
2018-12-19 |
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: Interim results of a randomized, phase 2 trial (AT
|
Boku, N;Ryu, MH;Kato, K;Chung, HC;Minashi, K;Lee, KW;Cho, H;Kang, WK;Komatsu, Y;Tsuda, M;Yamaguchi, K;Hara, H;Fumita, S;Azuma, M;Chen, LT;Kang, YK |
| 國家衛生研究院 |
2018-11-22 |
Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with metastatic gastric cancer; a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS
|
Muro, K;Van Cutsem, E;Narita, Y;Pentheroudakis, G;Baba, E;Li, J;Ryu, MH;Zamaniah, WIW;Yong, WP;Yeh, KH;Kato, K;Lu, Z;Cho, BC;Nor, IM;Ng, M;Chen, LT;Nakajima, TE;Shitara, K;Kawakami, H;Tsushima, T;Yoshino, T;Lordick, F;Martinelli, E;Smyth, EC;Arnold, D;Minami, H;Tabernero, J;Douillard, JY |
| 國家衛生研究院 |
2018-11-22 |
Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with metastatic oesophageal cancer; a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS
|
Muro, K;Lordick, F;Tsushima, T;Pentheroudakis, G;Baba, E;Lu, Z;Cho, BC;Nor, IM;Ng, M;Chen, LT;Kato, K;Li, J;Ryu, MH;Zamaniah, WIW;Yong, WP;Yeh, KH;Nakajima, TE;Shitara, K;Kawakami, H;Narita, Y;Yoshino, T;Van Cutsem, E;Martinelli, E;Smyth, EC;Arnold, D;Minami, H;Tabernero, J;Douillard, JY |
| 國家衛生研究院 |
2017-12 |
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial
|
Kang, YK;Boku, N;Satoh, T;Ryu, MH;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yeh, KH;Yoshikawa, T;Oh, SC;Bai, LY;Tamura, T;Lee, KW;Hamamoto, Y;Kim, JG;Chin, K;Oh, DY;Minashi, K;Cho, JY;Tsuda, M;Chen, LT |
| 國家衛生研究院 |
2017-10 |
Anti-angiogenic therapy in patients with advanced gastric and gastroesophageal junction cancer: A systematic review
|
Chen, LT;Oh, DY;Ryu, MH;Yeh, KH;Yeo, W;Carlesi, R;Cheng, R;Kim, J;Orlando, M;Kang, YK |
| 國家衛生研究院 |
2017-02 |
Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastroesophageal junction cancer (AGC): A double-blinded, randomized, phase III trial
|
Kang, YK;Satoh, T;Ryu, MH;Chao, Y;Kato, K;Chung, HC;Chen, JS;Muro, K;Kang, WK;Yoshikawa, T;Oh, SC;Tamura, T;Lee, KW;Boku, N;Chen, LT |
| 國家衛生研究院 |
2016-10 |
Asian consensus guidelines for the diagnosis and management of gastrointestinal stromal tumor
|
Koo, DH;Ryu, MH;Kim, KM;Yang, HK;Sawaki, A;Hirota, S;Zheng, J;Zhang, B;Tzen, CY;Yeh, CN;Nishida, T;Shen, L;Chen, LT;Kang, YK |
Showing items 1-14 of 14 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
